Orchestra BioMed Holdings (OBIO) Other financing activities (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Other financing activities for 5 consecutive years, with $26000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities fell 71.43% year-over-year to $26000.0; the TTM figure through Mar 2026 stood at $26000.0 (down 91.69% YoY), while the FY2025 annual figure was $91000.0, down 62.08% from the prior year.
• Other financing activities declined to $26000.0 in Q1 2026 per OBIO's latest filing, from $91000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $56.8 million in Q3 2023 and bottomed at $1000.0 in Q1 2023.
• Historically, Other financing activities has averaged $5.2 million across 5 years, with a median of $42000.0 in 2022.
• On a YoY basis, Other financing activities climbed as much as 135107.14% in 2023 and fell as far as 98.65% in 2023.
• Orchestra BioMed Holdings' Other financing activities stood at $42000.0 in 2022, then soared by 135107.14% to $56.8 million in 2023, then slumped by 99.91% to $51000.0 in 2024, then surged by 78.43% to $91000.0 in 2025, then sank by 71.43% to $26000.0 in 2026.
• Business Quant data shows OBIO's Other financing activities at $26000.0 in Q1 2026, $91000.0 in Q1 2025, and $51000.0 in Q4 2024.